Soured consumers see plans less favorably

Here’s what you missed this week on Managed Healthcare Executive.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.

All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host disease prophylaxis.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and have limited treatment options.

The findings were consistent with those seen in a study of Western study participants.